about
Imaging biomarkers in primary brain tumours.Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma.Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey.Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review.Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomasPhase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumorsMultimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma.Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumoursA Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosisReproducibility of the WHO classification of thymomas: practical implicationsHigh-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: a critical review.Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports.Infertility risk and teratogenicity of molecularly targeted anticancer therapy: A challenging issue.Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma.Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study.Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study.Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy.Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.Correlation of microvascular fractal dimension with positron emission tomography [(11)C]-methionine uptake in glioblastoma multiforme: preliminary findings.Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme.Neutrophils in Gliomas.Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience.Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma.Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma.Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis.Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution.Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma.Value of Surgical Resection in Patients with Newly Diagnosed Grade III Glioma Treated in a Multimodal Approach: Surgery, Chemotherapy and Radiotherapy.Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top"Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/CarboplatinPhase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumorsHerpes infections in breast cancer patients treated with adjuvant chemotherapyRetreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesotheliomaVinorelbine in pemetrexed-pretreated patients with malignant pleural mesotheliomaIs surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessmentRole of myeloid cells in the immunosuppressive microenvironment in gliomasLower Grade Gliomas: Relationships Between Metabolic and Structural Imaging with Grading and Molecular Factors
P50
Q30880129-673D2BE9-B548-4BCC-9EC5-2CF439DD0269Q33433311-491526F0-FF5A-4E70-9B5C-500847843D15Q33918135-D0127746-21E1-439B-BBCB-431F82448B06Q34349003-C3602B1E-98A8-449F-9CBE-374A58B18EADQ34675581-665E3A70-BBDE-40FC-A353-63540CCEFFC3Q34964958-9674C19C-0019-4599-B2E8-24228AE0F1F3Q35676452-F744B7ED-E8A1-4EE3-8AA6-002DFB52331BQ36557802-4AEFD20C-0421-40B7-BC75-6AC1C90387BAQ36557901-918F0667-A34E-4EF8-BFF0-BB70E3084B6DQ36617625-C5FA28FB-4908-4534-A9B3-4DDE0B96EC60Q37066558-6CECC09E-287B-4AAA-89C5-20BBD69257CEQ38400475-931A0E5B-910F-4D7E-821A-A9BA3EB6EBF0Q39002523-B30E9C07-A785-446C-B2DB-9A30FC851100Q39007387-01BA3695-30B2-467E-ADD6-328334DEC4EBQ39202948-604567E5-55C1-46D5-8DB4-52F4713FD5ABQ42366567-2552008D-5ADE-457D-AB7C-005D4781A409Q42373344-5ACC18A8-DF69-4F97-AF11-A53DA904E548Q43091608-BF8B8111-FE52-4836-8DB6-8C736559A7BAQ43098306-D9D1E145-93B1-489C-8502-60EABD80F35DQ43476617-B485C42B-7F8A-4259-AF22-8AB90F0D41A2Q43749590-C2F2DC2E-F34B-4E17-AAB9-0149E75BAE0BQ44343748-B114A94F-D168-4D44-B6E5-A383F96C7891Q48156165-F2C71909-82DA-4B39-AE1E-9273F0878B91Q48387795-6479BC2B-F6EB-4D4B-ACBC-15C01309FB59Q48488244-14437F2F-2243-4405-8C08-01BB61EE0045Q50124280-4741B564-4518-4176-BC24-98555DDC5C54Q50526883-7B214A8D-E7D9-45FF-AA8D-C2A9F31ABE22Q52750601-F167CD59-75CC-40FE-AF66-E492409A6FC7Q54597286-B1C2EC59-511A-41FE-BA72-A338BD559CDDQ55459309-9BC7B1F8-CEE0-4479-A724-98AC502F6DDFQ56889365-8DFD6D47-75D8-4EA7-BD8B-D2ED3C917057Q57890679-D6CDF273-B399-48C3-972C-24B20076244DQ57972640-263B60C0-A980-4BEE-8F18-255D26F3D7C7Q80643017-FDB09380-6633-4153-87B1-A199DD58A499Q83153976-665F431F-2593-40A9-AF62-740C94F71004Q86920950-37079861-415C-460C-8FAD-AF4A23ECD5ACQ89414622-A99FE192-7BB9-4E2C-9EE3-E57349BAA0BDQ91193257-D13F840B-1D4B-4850-8081-6606F053912AQ91857089-82351604-A126-4D59-AAD2-BDA1605B7957
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Matteo Simonelli
@ast
Matteo Simonelli
@en
Matteo Simonelli
@es
Matteo Simonelli
@nl
Matteo Simonelli
@sl
type
label
Matteo Simonelli
@ast
Matteo Simonelli
@en
Matteo Simonelli
@es
Matteo Simonelli
@nl
Matteo Simonelli
@sl
prefLabel
Matteo Simonelli
@ast
Matteo Simonelli
@en
Matteo Simonelli
@es
Matteo Simonelli
@nl
Matteo Simonelli
@sl
P1053
K-3364-2017
P106
P1153
15832774300
P21
P31
P3835
matteo-simonelli
P496
0000-0002-5264-1251